Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07527923 | First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis | PHASE1 | NOT YET_RECRUITING | 136 | — | — | May 4, 2026 | Jun 9, 2028 | Apr 14, 2026 | - | — |
| Arm | Type | Description |
|---|---|---|
| Part A | EXPERIMENTAL | - |
| Part B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| REGN20423 | DRUG | Administered per the protocol |
| Placebo | OTHER | Administered per the protocol |
Part A: Enrolls healthy participants Part B: Enrolls participants with atopic dermatitis Key Inclusion Criteria: Part A: 1. Is judged by the investigator to be in good health based on medical history, physical examination, vital signs, Electrocardiograms (ECGs), and laboratory safety testing at s...